Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...

U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its ...

Fintel reports that on January 27, 2025, Keefe, Bruyette & Woods downgraded their outlook for Federal National Mortgage ...

Decided to add this retail giant to your portfolio? Here's what you need to know before buying Amazon stock. Many, or all, of the products featured on this page are from our advertising partners ...

The key, of course, is to know which growth stocks to buy and when. Some growth stocks fell much more, with stock prices cut by half or two-thirds. But growth stocks rebounded in 2023, outpacing ...

The Magnificent Seven have been under pressure recently because of criticism their stock prices may have shot too high after leading the market for so many years. Such worries grew after Treasury ...

while trimming our Sep-25E target price by 6 per cent to Rs 1,570 due to 10% cut in Retail multiple. New energy development and vertical monetization are key triggers for the stock," it said.

A price hike is coming for folks with five or more lines on current plans and those still holding on to venerable plans no longer offered. David Lumb is a mobile reporter covering how on-the-go ...

Netflix Inc.’s stock was flat Friday after Benchmark analysts reiterated their sell rating on the stock even as they raised their price target by 30%, arguing that it’s looking overvalued in a ...

Futures higher, Trump issues range of executive orders - what's moving markets By Investing.com - 13 minutes ago Investing.com - US stock futures ticked up as markets prepared to begin a ...